Jinxin Fertility Group Ltd. (1951) AI Stock Analysis

• Market Cap: HK$6.89B
• Dividend Yield: 2.37%
• Average Volume (3M): 20.39M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.44
• Revenue Growth: -8.56%
• EPS Growth: -403.12%
• Country: HK
• Employees: 3,198
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): -0.43
• Shares Outstanding: 2,757,706,000
• 10 Day Avg. Volume: 23,635,980
• 30 Day Avg. Volume: 20,391,502
• PEG Ratio: -1.52
• Price to Book (P/B): 0.70
• Price to Sales (P/S): 2.54
• P/FCF Ratio: 14.62
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -0.37
• Revenue Forecast (FY): HK$2.92B

• Rating: 55 Neutral
• Price Target: HK$2.50 ▲(0.81% Upside)

Jinxin Fertility Group's strong financial performance is the most significant factor, showcasing consistent revenue growth and solid profitability. However, technical analysis indicates a bearish trend, and the negative P/E ratio suggests earnings challenges, which weigh down the overall score. The attractive dividend yield provides some support but is not enough to offset the negative technical and valuation signals.

Positive Factors

Strong Financial Position

The company's robust financial health, characterized by consistent revenue growth and solid profitability, ensures long-term stability and operational efficiency, supporting sustainable business expansion.

Prudent Financial Leverage

Prudent leverage and strong equity base provide financial resilience, enabling the company to withstand economic fluctuations and invest in growth opportunities without over-reliance on debt.

Efficient Cash Flow Management

Positive and growing operating cash flow enhances financial flexibility, allowing the company to reinvest in its business, manage liabilities, and pursue strategic initiatives effectively.

Negative Factors

Revenue Decline

A decline in revenue growth poses a challenge to maintaining market position and profitability, potentially impacting long-term business sustainability and competitive advantage.

Earnings Challenges

Negative earnings growth suggests operational difficulties, which could hinder the company's ability to generate profits and reinvest in business development, affecting long-term growth prospects.

Decreasing Gross Profit Margin

A decreasing gross profit margin reflects rising costs or pricing pressures, which can erode profitability and limit the company's ability to maintain competitive pricing or invest in growth.

Jinxin Fertility Group Ltd. Business Overview & Revenue Model

Company Description

Jinxin Fertility Group Limited, an investment holding company, provides assisted reproductive services (ARS) in China and the United States. The company primarily offers two treatment solutions, including artificial insemination that is performed with either husband's sperm or a donor sperm; and IVF technology, whereby fertilization is achieved through conventional in vitro fertilization and embryo transfer or IVF with intracytoplasmic sperm injection. It also provides related services, such as nutrition guidance, Chinese medicine treatment, and psychological counseling to support the ARS. In addition, the company offers management services; medical services in the areas of gynecology, urology, and internal medicine; ambulatory surgery center facilities services; and ancillary medical services. Further, it offers pre-implantation genetic screening testing services; and engages in the investment management and management consultancy, and real estate development and operation activities. Jinxin Fertility Group Limited was founded in 2003 and is headquartered in Chengdu, China.

How the Company Makes Money

Jinxin Fertility Group generates revenue primarily through the provision of fertility treatments and services, with key revenue streams including fees for IVF procedures, consultations, and associated medical services. The company also earns income from ancillary services such as genetic testing and egg donation programs. Additionally, Jinxin Fertility may enter into partnerships with hospitals, healthcare providers, and pharmaceutical companies, enhancing its service offerings and expanding its market reach. The growing demand for fertility services in China, driven by societal trends and increasing awareness of reproductive health, further contributes to the company's earnings potential.

Jinxin Fertility Group Ltd. Financial Statement Overview

Summary

Jinxin Fertility Group demonstrates a strong financial position with consistent revenue growth, solid profitability, and efficient cash flow management. The balance sheet shows prudent leverage and strong equity, while operational efficiency is reflected in healthy margins and cash flow metrics.

Income Statement

Jinxin Fertility Group has shown consistent revenue growth over the years, with a notable increase in total revenue from 2020 to 2024. The gross profit margin has slightly decreased recently, indicating rising costs or pricing pressures. However, the company maintains healthy EBIT and EBITDA margins, demonstrating efficient operations and profitability.

Balance Sheet

The company has a strong equity base with a favorable debt-to-equity ratio, indicating prudent financial leverage. The return on equity remains strong, reflecting effective use of shareholders' funds. The equity ratio has increased over the years, highlighting a solid financial foundation and asset management.

Cash Flow

Operating cash flow has been positive and growing, supporting ongoing operations. The free cash flow, although fluctuating, has improved recently, enhancing financial flexibility. The operating cash flow to net income ratio is robust, indicating strong cash earnings conversion.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.66B	2.81B	2.79B	2.36B	1.84B	1.43B
Gross Profit	907.85M	1.10B	1.18B	913.13M	771.48M	565.78M
EBITDA	389.14M	645.06M	682.02M	476.21M	494.08M	331.91M
Net Income	-946.50M	283.10M	344.72M	121.12M	339.90M	251.62M
Balance Sheet
Total Assets	14.01B	14.98B	14.90B	15.23B	12.83B	9.16B
Cash, Cash Equivalents and Short-Term Investments	719.77M	570.82M	852.90M	1.40B	1.93B	2.47B
Total Debt	2.92B	2.71B	2.55B	4.16B	2.09B	406.87M
Total Liabilities	4.76B	4.63B	4.71B	6.50B	4.07B	1.70B
Stockholders Equity	9.19B	10.27B	10.09B	8.64B	8.55B	7.28B
Cash Flow
Free Cash Flow	338.55M	489.30M	510.92M	-417.65M	263.62M	41.89M
Operating Cash Flow	513.33M	629.20M	684.48M	541.74M	343.45M	308.04M
Investing Cash Flow	-434.61M	-293.27M	-375.04M	-1.38B	-1.57B	1.15B
Financing Cash Flow	-95.17M	-458.29M	-950.45M	460.14M	955.05M	-55.58M

Jinxin Fertility Group Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.48
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1951, the sentiment is Positive. The current price of 2.48 is above the 20-day moving average (MA) of 2.46, above the 50-day MA of 2.47, and below the 200-day MA of 2.85, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 52.48 is Neutral, neither overbought nor oversold. The STOCH value of 53.03 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1951.

Jinxin Fertility Group Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1526	66 Neutral	HK$1.46B	5.04	20.47%	4.89%	-3.56%	-17.45%
2273	66 Neutral	HK$6.92B	18.72	14.86%	2.57%	16.41%	32.97%
2373	66 Neutral	HK$6.20B	21.12	31.23%	1.97%	28.53%	22.34%
6078	62 Neutral	HK$7.89B	16.06	6.78%	―	-13.92%	-36.32%
1951	55 Neutral	HK$6.89B	-6.61	-9.67%	2.37%	-8.56%	-403.12%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
3309	47 Neutral	HK$2.05B	-17.51	-6.41%	1.20%	2.05%	-285.88%

Jinxin Fertility Group Ltd. Corporate Events

Jinxin Fertility Group Approves 2025 Share Scheme at Extraordinary General Meeting

Jinxin Fertility Group Ltd. held an Extraordinary General Meeting on December 5, 2025, where all proposed resolutions were passed by poll. The key resolution approved was the adoption of the 2025 Share Scheme, which allows for the issuance and allotment of shares under share awards and options, subject to the approval of the Hong Kong Stock Exchange. This move is expected to enhance the company’s operational flexibility and potentially improve its market positioning by incentivizing eligible persons through share-based awards.

Jinxin Fertility Group Announces Share Repurchase Plan

Jinxin Fertility Group Ltd. has announced a proposed on-market share repurchase, allowing the company to buy back up to 10% of its total issued shares. This move is intended to reflect the company’s confidence in its business prospects and to potentially enhance shareholder value, while maintaining a solid financial position.

Jinxin Fertility Group Announces EGM and 2025 Share Scheme Details

Jinxin Fertility Group Limited has announced the book closure period for its Extraordinary General Meeting (EGM) scheduled for December 5, 2025. The meeting will address the proposed adoption of the 2025 Share Scheme, the conditional grant of options to Mr. Dong Yang, and the re-election of Mr. Chen Shuyun as a non-executive director. The register of members will be closed from December 3 to December 5, 2025, to determine shareholder entitlements for voting at the EGM. A circular with detailed information will be sent to shareholders on November 19, 2025.

Jinxin Fertility Group Announces 2025 Share Scheme to Boost Market Position

Jinxin Fertility Group Ltd. has announced an extraordinary general meeting to approve the adoption of a 2025 Share Scheme. This scheme includes granting share awards and options to eligible participants, with a significant allocation to Mr. Dong Yang, the company’s CEO and Acting CFO. The initiative aims to enhance the company’s operational capabilities and align management incentives with shareholder interests, potentially impacting its market positioning positively.

Jinxin Fertility Group Delays Circular Dispatch for 2025 Share Scheme

Jinxin Fertility Group Ltd. announced a further delay in the dispatch of a circular related to the 2025 Share Scheme and conditional grant of options and restricted shares to its directors and senior management. The delay is due to the need for additional time to prepare and finalize the necessary information, with the new dispatch date expected on or before November 25, 2025. This postponement may impact the company’s operational timeline and stakeholder expectations.

Jinxin Fertility Announces Changes in Company Secretarial Roles

Jinxin Fertility Group Limited announced changes in its company secretarial positions, with Ms. Zhai Yangyang and Ms. Ng Sau Mei resigning from their roles as joint company secretaries and authorized representative, effective October 31, 2025. Ms. Chung Man Nar Mona has been appointed as the new company secretary and authorized representative, bringing over 25 years of experience in corporate governance and compliance. The board expressed gratitude to the outgoing secretaries and welcomed Ms. Chung to her new role.

Jinxin Fertility Group Reports Improved IVF Treatment Cycle Trends

Jinxin Fertility Group Limited announced a slowdown in the decrease of IVF treatment cycles for the nine months ending September 30, 2025, compared to the previous year. The company’s flagship hospital in Chengdu showed significant improvement, while the Shenzhen hospital’s progress was slower due to an upcoming relocation. In the U.S., the delay in implementing a California bill affected treatment cycles, aligning with expectations. The company is confident in its long-term growth prospects, supported by favorable policies and operational improvements.

Jinxin Fertility Group Delays Circular Dispatch for 2025 Share Scheme

Jinxin Fertility Group Ltd. announced a delay in the dispatch of a circular related to the proposed adoption of the 2025 Share Scheme and conditional grant of options and restricted shares to its directors and senior management. The delay is due to the need for additional time to prepare and finalize the necessary information, with the new dispatch date set on or before November 11, 2025. This postponement may affect the timeline for shareholder engagement and decision-making regarding the share scheme.

Jinxin Fertility Proposes 2025 Share Scheme to Align Interests

Jinxin Fertility Group Ltd. has announced a proposed adoption of the 2025 Share Scheme, aiming to align the interests of its directors and key employees with the company’s long-term growth objectives. The scheme includes conditional grants of options and restricted shares to management and non-executive grantees, pending shareholder approval at an upcoming extraordinary general meeting.

Jinxin Fertility Announces Board Changes with New Non-Executive Director

Jinxin Fertility Group Ltd. announced a change in its board composition with the resignation of Mr. Fang Min as a non-executive director and his replacement by Mr. Shuyun Chen, effective immediately. Mr. Chen brings extensive experience from his previous roles in investment and healthcare sectors, which could enhance the company’s strategic direction and governance.

Jinxin Fertility Group Announces Board Composition and Committee Roles

Jinxin Fertility Group Limited has announced the composition of its board of directors and the roles within its various committees. The announcement highlights the leadership structure and the strategic roles assigned to each director, which are crucial for the company’s governance and operational strategy. This organizational update is expected to enhance the company’s decision-making processes and maintain its commitment to medical quality and research and development.